GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TScan Therapeutics Inc (NAS:TCRX) » Definitions » Price-to-Owner-Earnings

TScan Therapeutics (TScan Therapeutics) Price-to-Owner-Earnings : (As of May. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is TScan Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-15), TScan Therapeutics's share price is $8.99. TScan Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for TScan Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


TCRX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.165
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-15), TScan Therapeutics's share price is $8.99. TScan Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.79. Therefore, TScan Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-15), TScan Therapeutics's share price is $8.99. TScan Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.79. Therefore, TScan Therapeutics's PE Ratio without NRI for today is At Loss.


TScan Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for TScan Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TScan Therapeutics Price-to-Owner-Earnings Chart

TScan Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - - -

TScan Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TScan Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, TScan Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TScan Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where TScan Therapeutics's Price-to-Owner-Earnings falls into.



TScan Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

TScan Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=8.99/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TScan Therapeutics  (NAS:TCRX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


TScan Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of TScan Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


TScan Therapeutics (TScan Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
830 Winter Street, Waltham, MA, USA, 02451
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Executives
Timothy J Barberich director 40 ELM ST, CONCORD MA 01752
Barbara Klencke director C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Leiden Dworak officer: Chief Accounting Officer C/O TSCAN THERAPEUTICS, INC., 880 WINTER STREET, WALTHAM MA 02451
Lynx1 Capital Management Lp 10 percent owner 151 CALLE DE SAN FRANCISCO, SUITE 200 PMB 1237, SAN JUAN PR 00901-1607
Weston Nichols 10 percent owner C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Brian M. Silver officer: Chief Financial Officer C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Debora Barton officer: Chief Medical Officer C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
David P Southwell director, officer: Chief Executive Officer C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014